Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus - Scorecard - MDSpire

Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

  • By

  • Shaoqin Yang

  • Shuangshuang Zhang

  • Yuming Gu

  • June 15, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of the Safety and Efficacy of Combined TACE-HAIC and Targeted Immunotherapy in Patients with Primary Liver Cancer and Portal Vein Tumor Thrombus

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with HCC and PVTT.
Care Setting

Key Highlights

  • highlight_1
  • highlight_2

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • I
        • n
        • c
        • l
        • u
        • d
        • e
        • s
        • p
        • e
        • c
        • i
        • f
        • i
        • c
        • a
        • d
        • v
        • e
        • r
        • s
        • e
        • e
        • v
        • e
        • n
        • t
        • s
        • a
        • s
        • s
        • o
        • c
        • i
        • a
        • t
        • e
        • d
        • w
        • i
        • t
        • h
        • T
        • A
        • C
        • E
        • a
        • n
        • d
        • H
        • A
        • I
        • C
        • .

        Patient & Prescribing Data

        Clinical Best Practices

        • monitoring

        Related Resources & Content

        Original Source(s)

        Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

        • by Shaoqin Yang, Shuangshuang Zhang, Yuming Gu

        • June 15, 2026

        Related Content

        Meningeal immunity and “Interstitial” therapy: a new paradigm for immunotherapy in glioblastoma

        An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy

        The role of LARP1 in breast cancer progression: from prognosis to immune microenvironment remodeling